By combining Renatus’ proprietary cholesterol modulator and Carbohyde’s expertise in medicinal chemistry, the agreement aims to derive novel cholesterol modulators with improved CNS delivery.
Carbohyde is a pharma company specialized in developing carbohydrate-based APIs led by experts in carbohydrate chemistry, analysis, and pharmaceutical development. The company’s primary focus is neurodegenerative diseases, yet they have various programs in various unmet medical indications.
Renatus is specialized in developing cyclodextrin-based cholesterol modulators. The company’s chronic kidney disease program is currently in an IND-enabling stage, looking to complete the IND application by 2025. The company is developing pipelines for other cholesterol-driven diseases including CNS diseases.
“We have been following the technology of Renatus for a long time and built this relationship brick-by-brick. Our philosophy is that we can achieve much more with joint efforts, and this partnership will bring out the best of each partner, I am sure” as Tamas Sohajda, a member of CarboHyde’s scientific board shared his views on this strategic collaboration.
“Our proprietary cyclodextrin exhibits a superior safety profile over hydroxypropyl beta-cyclodextrin, which is currently in clinical trials for several cholesterol-driven diseases. Ototoxicity is a dose-limiting toxicity of the clinical-stage cyclodextrin and leads to irreversible hearing loss. It can induce kidney injury in some cases. However, our cyclodextrin injected at higher doses failed to induce such toxicity. Besides safety, it has shown greater efficacy in normalizing cholesterol homeostasis in some of the cholesterol-associated disease models we are exploring. I am very pleased to work with Carbohyde. We have a lot in common and share a common vision. The collaboration will significantly promote the application of our cyclodextrin for CNS diseases wherein cholesterol is causing trouble,” said Heegon Kim, CEO of Renatus.
